Telix Pharmaceuticals Limited (NASDAQ:TLX) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX) have received a consensus recommendation of “Moderate Buy” from the eight analysts that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, five have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $21.00.

Several research firms have recently issued reports on TLX. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Telix Pharmaceuticals in a research note on Tuesday, July 7th. Weiss Ratings reissued a “sell (d)” rating on shares of Telix Pharmaceuticals in a research report on Monday, April 20th. Citigroup cut their price target on shares of Telix Pharmaceuticals from $22.50 to $22.00 and set a “buy” rating on the stock in a report on Tuesday, July 7th. Wall Street Zen raised shares of Telix Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, April 11th. Finally, Wedbush reissued an “outperform” rating and set a $22.00 target price on shares of Telix Pharmaceuticals in a research report on Monday, July 6th.

Telix Pharmaceuticals Price Performance

NASDAQ TLX opened at $11.02 on Wednesday. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.43 and a quick ratio of 1.27. The business has a fifty day simple moving average of $10.35 and a 200 day simple moving average of $9.01. Telix Pharmaceuticals has a 12 month low of $6.28 and a 12 month high of $16.94.

Insider Activity at Telix Pharmaceuticals

In other Telix Pharmaceuticals news, CEO Christian Behrenbruch purchased 33,435 shares of the firm’s stock in a transaction that occurred on Wednesday, April 29th. The stock was bought at an average cost of $14.87 per share, with a total value of $497,178.45. Following the completion of the transaction, the chief executive officer owned 20,742,935 shares of the company’s stock, valued at $308,447,443.45. The trade was a 0.16% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Rhumbline Advisers grew its stake in Telix Pharmaceuticals by 117.3% in the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock valued at $25,000 after purchasing an additional 1,392 shares during the period. XTX Topco Ltd bought a new stake in shares of Telix Pharmaceuticals during the 4th quarter worth $89,000. Bank of America Corp DE raised its stake in shares of Telix Pharmaceuticals by 523.8% during the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock worth $96,000 after purchasing an additional 8,423 shares during the period. OLD Mission Capital LLC purchased a new stake in Telix Pharmaceuticals during the fourth quarter worth about $111,000. Finally, XY Capital Ltd bought a new stake in Telix Pharmaceuticals in the first quarter worth about $120,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.